SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-138272
Filing Date
2024-05-14
Accepted
2024-05-14 16:21:45
Documents
14
Period of Report
2024-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d825581d8k.htm   iXBRL 8-K 24803
2 EX-99.1 d825581dex991.htm EX-99.1 71015
  Complete submission text file 0001193125-24-138272.txt   233407

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vinc-20240514.xsd EX-101.SCH 2838
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vinc-20240514_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vinc-20240514_pre.xml EX-101.PRE 11699
17 EXTRACTED XBRL INSTANCE DOCUMENT d825581d8k_htm.xml XML 3767
Mailing Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306
Business Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306 650-800-6676
Vincerx Pharma, Inc. (Filer) CIK: 0001796129 (see all company filings)

IRS No.: 833197402 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39244 | Film No.: 24944706
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)